Literature DB >> 28918542

Current chemotherapeutic regimens for brain metastases treatment.

Joo Yeon Nam1, Barbara J O'Brien2.   

Abstract

Brain metastasis is a common complication in advanced systemic cancer, with an increasing incidence. The diagnosis of brain metastasis historically portended a dismal prognosis. The successful development of effective treatments for patients with brain metastasis is complicated by the differences among cancer subtypes, the limited understanding of the underlying pathophysiology of BM, the impact of the blood-brain barrier, and other factors. There is now renewed interest in treating this often devastating complication of cancer, and in understanding the underlying mechanisms of disease in this "sanctuary" site. Promising treatment strategies include brain-penetrant targeted therapies and immunotherapy, and strategies for enhanced delivery of therapy. This review highlights a selection of these approaches.

Entities:  

Keywords:  Blood brain barrier; Brain metastasis; Immunotherapy; Targeted therapy

Mesh:

Substances:

Year:  2017        PMID: 28918542     DOI: 10.1007/s10585-017-9861-y

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  91 in total

1.  Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.

Authors:  T Iuchi; M Shingyoji; T Sakaida; K Hatano; O Nagano; M Itakura; H Kageyama; S Yokoi; Y Hasegawa; K Kawasaki; T Iizasa
Journal:  Lung Cancer       Date:  2013-08-28       Impact factor: 5.705

2.  Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Authors:  Shirish M Gadgeel; Leena Gandhi; Gregory J Riely; Alberto A Chiappori; Howard L West; Michele C Azada; Peter N Morcos; Ruey-Min Lee; Linta Garcia; Li Yu; Frederic Boisserie; Laura Di Laurenzio; Sophie Golding; Jotaro Sato; Shumpei Yokoyama; Tomohiro Tanaka; Sai-Hong Ignatius Ou
Journal:  Lancet Oncol       Date:  2014-08-18       Impact factor: 41.316

Review 3.  Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier.

Authors:  K E Parrish; J N Sarkaria; W F Elmquist
Journal:  Clin Pharmacol Ther       Date:  2015-02-18       Impact factor: 6.875

4.  Epidemiology of brain metastases.

Authors:  Lakshmi Nayak; Eudocia Quant Lee; Patrick Y Wen
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

5.  Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study.

Authors:  Tomoya Kawaguchi; Yasuhiro Koh; Masahiko Ando; Norimasa Ito; Sadanori Takeo; Hirofumi Adachi; Tsutomu Tagawa; Seiichi Kakegawa; Motohiro Yamashita; Kazuhiko Kataoka; Yukito Ichinose; Yukiyasu Takeuchi; Masakuni Serizawa; Akihiro Tamiya; Shigeki Shimizu; Naoki Yoshimoto; Akihito Kubo; Shun-Ichi Isa; Hideo Saka; Akihide Matsumura
Journal:  J Clin Oncol       Date:  2016-05-09       Impact factor: 44.544

Review 6.  Developments in pharmacotherapy for treating metastatic non-small cell lung cancer.

Authors:  Antonio Rossi; Paola Claudia Sacco; Giuseppe Santabarbara; Assunta Sgambato; Francesca Casaluce; Giovanni Palazzolo; Paolo Maione; Cesare Gridelli
Journal:  Expert Opin Pharmacother       Date:  2017-01-20       Impact factor: 3.889

7.  Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.

Authors:  R Porta; J M Sánchez-Torres; L Paz-Ares; B Massutí; N Reguart; C Mayo; P Lianes; C Queralt; V Guillem; P Salinas; S Catot; D Isla; A Pradas; A Gúrpide; J de Castro; E Polo; T Puig; M Tarón; R Colomer; R Rosell
Journal:  Eur Respir J       Date:  2010-07-01       Impact factor: 16.671

8.  Convection-enhanced delivery of macromolecules in the brain.

Authors:  R H Bobo; D W Laske; A Akbasak; P F Morrison; R L Dedrick; E H Oldfield
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

Review 9.  Brain metastases.

Authors:  Jaime Gállego Pérez-Larraya; Jerzy Hildebrand
Journal:  Handb Clin Neurol       Date:  2014

10.  A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer.

Authors:  Ling Cai; Jian-fei Zhu; Xue-wen Zhang; Su-xia Lin; Xiao-dong Su; Peng Lin; Kai Chen; Lan-jun Zhang
Journal:  J Neurooncol       Date:  2014-08-07       Impact factor: 4.130

View more
  3 in total

1.  Curing brain metastases.

Authors:  Rahul Jandial
Journal:  Clin Exp Metastasis       Date:  2017-10       Impact factor: 5.150

2.  Identifying a 6-Gene Prognostic Signature for Lung Adenocarcinoma Based on Copy Number Variation and Gene Expression Data.

Authors:  Yisheng Huang; Liling Qiu; Xiaoye Liang; Jing Zhao; Haoting Chen; Zhiqiang Luo; Wanzhen Li; Xiaohua Lin; Jingjie Jin; Jian Huang; Gong Zhang
Journal:  Oxid Med Cell Longev       Date:  2022-09-28       Impact factor: 7.310

3.  Clinical features and prognostic factors in 190 cancer patients with brain metastases.

Authors:  Min-Hang Zhou; Yuan Wu; Jun-Zhong Sun
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.